Free shipping on all orders over $ 500

Tofogliflozin

Cat. No. M30847
Tofogliflozin Structure
Synonym:

CSG452

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

Chemical Information
Molecular Weight 386.44
Formula C22H26O6
CAS Number 903565-83-3
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Mani Pathak, et al. Eur J Clin Pharmacol. Impact of tofogliflozin on hepatic outcomes: a systematic review

[2] Yumie Takeshita, et al. Diabetes Care. Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial

[3] Masato Yoneda, et al. Hepatol Commun. Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial

[4] Kentaro Murakami, et al. Cells. Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis

[5] Masato Yoneda, et al. BMJ Open Diabetes Res Care. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Related SGLT Products
Tianagliflozin

Tianagliflozin is an SGLT2 inhibitor that may be used in studies related to type 2 diabetes.

JTT-662

JTT-662 is an SGLT1 inhibitor that can be used in studies related to type 2 diabetes.

JP-2266

JP-2266 is a dual SGLT1/2 inhibitor that can be used in studies related to diabetes.

Mizagliflozin

Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation.

Sergliflozin etabonate

Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.

  Catalog
Abmole Inhibitor Catalog




Keywords: Tofogliflozin, CSG452 supplier, SGLT, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.